Innovating epilepsy care
At Epiminder, we strive to transform epilepsy management through cutting-edge technology and patient-focused solutions.
Discover the journey of innovation at Epiminder since 2018
Epiminder was formed in 2018 by Professor Mark Cook as a research collaboration between the Bionics Institute, the University of Melbourne, St Vincent's Hospital Melbourne and Cochlear.
The partnership combined the technological expertise in epilepsy seizure monitoring of the three research institutions with Cochlear's proficiency in implant design, development and manufacturing.
Professor Mark Cook examining the Minder Implant device, the world's first FDA-authorised* implantable continuous EEG monitoring system
Key milestones in our journey
Since our founding in 2018, Epiminder has been dedicated to revolutionising epilepsy care. Our innovative technology aims to empower patients and improve their quality of life.
2018
Epiminder founded by Bionics Institute, Cochlear, St Vincent's Hospital and Melbourne University.
2018
Epiminder founded by Bionics Institute, Cochlear, St Vincent's Hospital and Melbourne University.
2019
Epiminder develops prototype Minder implantable continuous EEG monitoring (iCEM) device, a multi-year duration ssEEG unit.
2019
Epiminder develops prototype Minder implantable continuous EEG monitoring (iCEM) device, a multi-year duration ssEEG unit.
2019
UMPIRE clinical study of Minder commences at St Vincent's hospital.
2019
UMPIRE clinical study of Minder commences at St Vincent's hospital.
2021
UMPIRE clinical study expanded to further hospital sites in Australia
2021
UMPIRE clinical study expanded to further hospital sites in Australia
2023
Minder receives FDA "Breakthrough" designation, for medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The Breakthrough Device Designation (BDD) program is intended to help patients have more timely access to medical devices by expediting their development, assessment, and review.
2023
Minder receives FDA "Breakthrough" designation, for medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The Breakthrough Device Designation (BDD) program is intended to help patients have more timely access to medical devices by expediting their development, assessment, and review.
2023
Professor Cook received the Order of Australia in recognition of his distinguished service to neurological medicine and research through contributions to the treatment of epilepsy.
2023
Professor Cook received the Order of Australia in recognition of his distinguished service to neurological medicine and research through contributions to the treatment of epilepsy.
2024
UMPIRE clinical study completes, with results demonstrating that Minder is both safe and has signal detection equivalent to a scalp EEG. The Minder system recorded continuous EEG for five years in a study participant—longest continuous EEG recording ever captured.
2024
UMPIRE clinical study completes, with results demonstrating that Minder is both safe and has signal detection equivalent to a scalp EEG. The Minder system recorded continuous EEG for five years in a study participant—longest continuous EEG recording ever captured.
2025
Epiminder received FDA marketing authorisation via the De Novo pathway allowing its sale and marketing in the US.
2025
Epiminder received FDA marketing authorisation via the De Novo pathway allowing its sale and marketing in the US.
2025
Epiminder announces the publication of the landmark UMPIRE clinical study in Australia, confirming the safety and efficacy of the Minder device
2025
Epiminder announces the publication of the landmark UMPIRE clinical study in Australia, confirming the safety and efficacy of the Minder device
Executive leadership
Our leadership team brings together expertise from neurology, biomedical engineering, and healthcare technology.
Dr Rohan Hoare
Chief Executive Officer
View bio
Prof Mark Cook, AO
Chief Medical Officer
View bio
Dr John Heasman
Chief Operating Officer
View bio
Mark McLellan
Chief Financial Officer and Company Secretary
View bio
Toby McSweeney
Chief Technology Officer and VP, Quality
View bio
Dr Tracy Cameron
VP, Clinical & Regulatory
View bio
Chip Moebus
VP, Market Access
View bio
Steven Ringo
VP, IT & Security
View bioBoard of Directors
Philip Binns
Chair
View bio
Dr Rohan Hoare
Chief Executive Officer & Managing Director
View bio
Robert Klupacs
Non-Executive Director
View bio
Donal O'Dwyer
Independent Non-Executive Director
View bio
Patricia O'Rourke
Non-Executive Director
View bio
Jeff Sells
Independent Non-Executive Director
View bio
Karen Campitelli
Company Secretary
View bioIn proud partnership with
